Actinium Pharmaceuticals Inc (ATNM)

$1.67 +0.24 (16.78%)
Market Cap 44.61M
Revenue (ttm) 0.00
Net Income (ttm) -38.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,888,000
Avg Vol 178,686
Day's Range N/A - N/A
Shares Out 31.20M
Stochastic %K 80%
Beta -0.25
Analysts Strong Sell
Price Target $5.00

Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 677 3870
Address:
100 Park Avenue, 23rd Floor, New York, United States
gooddoggie
gooddoggie Oct. 25 at 7:57 PM
$ATNM 2B no prob.
2 · Reply
luzongeezer
luzongeezer Oct. 25 at 12:39 PM
$ATNM Would love to see it get moving too. Not holding my breath.
0 · Reply
kmers_bossman
kmers_bossman Oct. 25 at 12:11 AM
$ATNM holding a big bag would love to see this get moving again
0 · Reply
LosStockosDiablo
LosStockosDiablo Oct. 24 at 7:17 PM
$ATNM glad I never lost faith with this one. Still holding long.
1 · Reply
xlinkx
xlinkx Oct. 24 at 7:14 PM
$ATNM More news tomarrow on ATNM-400 use in lung cancer.
1 · Reply
ckruel
ckruel Oct. 24 at 7:09 PM
$ATNM heading to test 1.90 again, hopefully smash it
0 · Reply
gooddoggie
gooddoggie Oct. 24 at 7:08 PM
$ATNM We just need a little encouragement every once in a while.
1 · Reply
Biotrad3r
Biotrad3r Oct. 24 at 7:07 PM
$ATNM Its time for the Buyout / PPS chart to circulate again…
1 · Reply
DENDOG57
DENDOG57 Oct. 24 at 7:01 PM
$ATNM 100 bucks stock here?..... lets go
0 · Reply
timfris
timfris Oct. 24 at 6:41 PM
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study - PubMed $ATNM I’m sure Atnm will lap Novartis, J and J, Sanofli, and other big pharma that already funding Act 225 and prostate trials https://pubmed.ncbi.nlm.nih.gov/38218192/
0 · Reply
Latest News on ATNM
Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct 24, 2025, 8:30 AM EDT - 1 day ago

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 12:10 PM EDT - 12 days ago

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct 13, 2025, 8:30 AM EDT - 12 days ago

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Jul 31, 2025, 8:30 AM EDT - 3 months ago

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 23, 2025, 11:30 AM EDT - 4 months ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

May 22, 2025, 5:45 AM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

May 15, 2025, 1:43 PM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 14, 2025, 1:26 PM EDT - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

May 6, 2025, 8:45 AM EDT - 6 months ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Apr 30, 2025, 7:25 AM EDT - 6 months ago

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:30 AM EDT - 6 months ago

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 6 months ago

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Apr 24, 2025, 5:00 AM EDT - 6 months ago

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 19, 2025, 8:20 AM EDT - 6 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Apr 17, 2025, 5:45 AM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

Apr 16, 2025, 10:01 AM EDT - 6 months ago

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

IBTA

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)

Mar 28, 2025, 11:57 AM EDT - 7 months ago

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Mar 27, 2025, 8:45 AM EDT - 7 months ago

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

Mar 25, 2025, 6:00 AM EDT - 7 months ago

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

gooddoggie
gooddoggie Oct. 25 at 7:57 PM
$ATNM 2B no prob.
2 · Reply
luzongeezer
luzongeezer Oct. 25 at 12:39 PM
$ATNM Would love to see it get moving too. Not holding my breath.
0 · Reply
kmers_bossman
kmers_bossman Oct. 25 at 12:11 AM
$ATNM holding a big bag would love to see this get moving again
0 · Reply
LosStockosDiablo
LosStockosDiablo Oct. 24 at 7:17 PM
$ATNM glad I never lost faith with this one. Still holding long.
1 · Reply
xlinkx
xlinkx Oct. 24 at 7:14 PM
$ATNM More news tomarrow on ATNM-400 use in lung cancer.
1 · Reply
ckruel
ckruel Oct. 24 at 7:09 PM
$ATNM heading to test 1.90 again, hopefully smash it
0 · Reply
gooddoggie
gooddoggie Oct. 24 at 7:08 PM
$ATNM We just need a little encouragement every once in a while.
1 · Reply
Biotrad3r
Biotrad3r Oct. 24 at 7:07 PM
$ATNM Its time for the Buyout / PPS chart to circulate again…
1 · Reply
DENDOG57
DENDOG57 Oct. 24 at 7:01 PM
$ATNM 100 bucks stock here?..... lets go
0 · Reply
timfris
timfris Oct. 24 at 6:41 PM
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study - PubMed $ATNM I’m sure Atnm will lap Novartis, J and J, Sanofli, and other big pharma that already funding Act 225 and prostate trials https://pubmed.ncbi.nlm.nih.gov/38218192/
0 · Reply
prismmarketview
prismmarketview Oct. 24 at 5:45 PM
$ATNM + 16%. Actinium Pharmaceuticals unveiled new preclinical data for its next-generation radiotherapy ATNM-400, showing potent and durable efficacy in drug-resistant prostate cancer models. The therapy targets a non-PSMA antigen, demonstrating tumor control even where current treatments fail — a potential breakthrough for patients with limited options. https://prismmarketview.com/actiniums-atnm-400-delivers-breakthrough-efficacy-in-resistant-prostate-cancer-models-expanding-potential-for-next-generation-radiotherapy/
0 · Reply
timfris
timfris Oct. 24 at 4:25 PM
$ATNM someone might wanna ask the company if they have a patent on using ACT 225 for prostate cancer….because they don’t. A small study in Germany years ago proves it works. Company is grasping g at straws now.
1 · Reply
Moneytalkssss
Moneytalkssss Oct. 24 at 4:08 PM
$ATNM Beautiful.
0 · Reply
yellowjacker
yellowjacker Oct. 24 at 3:28 PM
$ATNM 1 million shares in the first 2 hours of the trading day. Someone has got the message. Lets see how we close on a Friday before the weekend.
0 · Reply
fucTYPE1diabetes
fucTYPE1diabetes Oct. 24 at 3:13 PM
$ATNM cannot deny what we have!
1 · Reply
RadioIsotope25
RadioIsotope25 Oct. 24 at 2:31 PM
$RADX RAD402 formed between MD anderson and Radiopharm Theranostics will enter the clinic end of year for Prostate Cancer. MD Anderson is the best cancer center in the world. $ATNM $LNTH $CLRB $CATX
1 · Reply
Mnur
Mnur Oct. 24 at 1:15 PM
$ATNM very strong update!
0 · Reply
timfris
timfris Oct. 24 at 12:50 PM
$ATNM if successful, should be getting approval some time in 2040, knowing this company.
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 24 at 12:48 PM
$ATNM Actinium Pharmaceuticals Presents New Preclinical Data For ATNM-400 Antibody Radioconjugate At 32nd Annual Prostate Cancer Foundation Scientific Retreat In Carlsbad, California
0 · Reply
DoYourOwnDue
DoYourOwnDue Oct. 24 at 12:32 PM
$ATNM https://ir.actiniumpharma.com/press-releases/detail/508
0 · Reply
Jimmy1940
Jimmy1940 Oct. 23 at 2:58 PM
$ATNM Market interest diminishes when the path to revenue becomes unclear, and any future attempts to raise capital may be more difficult or costly.
1 · Reply
englishkaren
englishkaren Oct. 23 at 2:28 PM
$ATNM The market is asleep on this, but the science itself is highly material: a non-PSMA Ac-225 construct achieving 99 % TGI in an osimertinib-resistant model is rare, and no other public radioconjugate program has shown that in EGFR-mutant NSCLC.
1 · Reply